Precision BioSciences stock barely flinched after earnings, edging only 0.9% higher to US$7.49. Yet the quarter itself was anything but quiet. The headline is a sharp swing back into loss making territory, with Q2 basic earnings per share at a loss of US$1.26 and revenue dropping to essentially zero. For a biotech that investors often value on future potential, the real story today is the strain this kind of income statement puts on the balance between patience and dilution risk. The price reaction looks muted compared with the pressure building under the surface.

Is Precision BioSciences a rare bargain at a reported DCF value of US$127.43 per share, or is the low P/S and heavy losses exactly what the price should reflect? Compare the current market price to the full valuation analysis for Precision BioSciences

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$0.0m vs. US$0.02m (revenue moved back to essentially flat levels quarter on quarter and year on year)
• Net Income, Q2 2026 vs. Q2 2025: loss of US$32.65m vs. loss of US$23.52m (loss widened year on year)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$1.26 per share vs. loss of US$2.13 per share (loss per share narrowed year on year)
• Trailing 12 Month Net Income, Q2 2026 vs. Q2 2025: loss of US$53.62m vs. loss of US$78.26m (full-year loss narrowed over the past 12 months)

Prefer clean, visual charts over another wall of earnings tables and raw figures? View Precision BioSciences' full financial picture, including a clear outline of its cash position and balance sheet strength, in the interactive company report for Precision BioSciences.

Precision BioSciences bull case meets mixed signals

The long term platform story around Precision BioSciences gets only partial support from these Q2 numbers. Trailing 12 month net loss narrowed to US$53.62m from US$78.26m, which fits a gradual improvement narrative. Loss per share in Q2 also narrowed to US$1.26 despite a larger absolute loss, hinting at earlier cost actions or a changed share count rather than clear operating momentum. With revenue sitting at US$0.0m, the platform and partnership upside story still rests almost entirely on future clinical and deal progress rather than current financial traction.

Bear case on cash burn and dilution risk

The bearish focus on funding risk and ongoing cash burn finds more support in this quarter. Precision BioSciences recorded a Q2 net loss of US$32.65m compared with a loss of US$23.52m a year earlier, so absolute losses increased even as trailing 12 month losses improved. Revenue also slipped back to US$0.0m, which reinforces the pre commercial profile. A modest 0.9% move in the share price after the release suggests the market had already priced in much of this risk, rather than seeing Q2 as a fresh negative shock.

Compare how that shrinking trailing loss and flat revenue profile stack up against Street expectations. See the consensus price target analysis for Precision BioSciences to check whether analysts think Precision BioSciences is on the right track or still off the pace.

Stay Ahead With Simply Wall St

If Precision BioSciences is on your radar after its Q2 loss profile and DCF gap, register for free with Simply Wall St and add it to your Watchlist to track share price moves against fair value and monitor for a potentially more attractive entry point. Once you are invested, use the Portfolio Command Center to cut through noise and stay on top of only the key developments that matter to your holdings. For longer term conviction building, tap into crowd insights and different thesis angles through the Community. By identifying potential catalysts and risks early, you may be able to stay ahead of the market over time.

Seeking Alternatives Beyond Precision BioSciences?

Some stocks are already building quiet momentum while most investors stay focused elsewhere. Fresh ideas can move quickly once the crowd catches up, so do your homework and get in early.

• Spot potential breakout compounders early by scanning the curated 19 high quality undiscovered gems, before renewed attention sends more investors chasing the same limited set of opportunities.
• Target resilience when markets start flying in different directions by reviewing the hand picked 78 resilient stocks with low risk scores, while these steadier companies still sit under the radar for now.
• Ride structural themes that are still building by assessing the carefully filtered 36 power grid technology and infrastructure stocks, before capital flows crowd into the same grid and infrastructure stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.